Chapter 43: LEARNING OBJECTIVES

On completion of this chapter, the reader will be able to:

1. Discuss the epidemiology and etiology of idiopathic Parkinson’s disease (PD).
2. Explain the basic pathophysiological mechanisms responsible for the motor features of PD.
3. List drugs that can exacerbate PD.
4. Describe the cardinal motor features and clinical presentation of PD.
5. List other conditions that may have motor features similar to PD.
7. Describe the pharmacology, clinical effects, and safety of anticholinergic drugs for the management of PD.
8. Describe the pharmacology, clinical effects, and safety of amantadine for the management of PD.
9. Describe the pharmacology, clinical effects, and safety of levodopa and peripheral decarboxylase inhibitors for the management of PD.
10. Describe the pharmacology, clinical effects, and safety of dopamine agonists for the management of PD.
11. Describe the pharmacology, clinical effects, and safety of catechol-O-methyltransferase (COMT) inhibitors for the management of PD.
12. Describe the pharmacology, clinical effects, and safety of monoamine oxidase (MAO-B) inhibitors for the management of PD.
13. Recognize the type of levodopa motor complication a patient is experiencing based on history and symptoms.
15. Develop a treatment plan for a patient with PD who is experiencing hallucinations and psychosis.